These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

911 related articles for article (PubMed ID: 26959310)

  • 1. Addressing epidermal growth factor receptor tyrosine kinase inhibitor resistance in non-small cell lung cancer.
    Noda S; Kanda S
    Expert Rev Respir Med; 2016; 10(5):547-56. PubMed ID: 26959310
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor -mutant non-small cell lung cancer.
    Tan CS; Cho BC; Soo RA
    Lung Cancer; 2016 Mar; 93():59-68. PubMed ID: 26898616
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dacomitinib in lung cancer: a "lost generation" EGFR tyrosine-kinase inhibitor from a bygone era?
    Ou SH; Soo RA
    Drug Des Devel Ther; 2015; 9():5641-53. PubMed ID: 26508839
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and updated therapy strategies in human nonsmall cell lung cancer.
    Zhang K; Yuan Q
    J Cancer Res Ther; 2016 Dec; 12(Supplement):C131-C137. PubMed ID: 28230005
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Can we define the optimal sequence of epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of epidermal growth factor receptor-mutant nonsmall cell lung cancer?
    Sun JM; Park K
    Curr Opin Oncol; 2017 Mar; 29(2):89-96. PubMed ID: 28085680
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Next-generation sequencing reveals novel resistance mechanisms and molecular heterogeneity in EGFR-mutant non-small cell lung cancer with acquired resistance to EGFR-TKIs.
    Lee CK; Kim S; Lee JS; Lee JE; Kim SM; Yang IS; Kim HR; Lee JH; Kim S; Cho BC
    Lung Cancer; 2017 Nov; 113():106-114. PubMed ID: 29110836
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Treatment strategy for activating EGFR-mutated non-small cell lung cancer after failure of first-generation EGFR-TKIs].
    Asami K
    Gan To Kagaku Ryoho; 2014 May; 41(5):533-8. PubMed ID: 24916999
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Mechanism and clinical efficacy of third-generation epidermal growth factor receptor tyrosine kinase inhibitor in non-small cell lung cancer].
    Chen XX; Zhou CC
    Zhonghua Zhong Liu Za Zhi; 2017 Jun; 39(6):401-404. PubMed ID: 28635227
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimal management of EGFR-mutant non-small cell lung cancer with disease progression on first-line tyrosine kinase inhibitor therapy.
    Liao BC; Lin CC; Lee JH; Yang JC
    Lung Cancer; 2017 Aug; 110():7-13. PubMed ID: 28676222
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of continuous EGFR-inhibition and role of Hedgehog in EGFR acquired resistance in human lung cancer cells with activating mutation of EGFR.
    Della Corte CM; Malapelle U; Vigliar E; Pepe F; Troncone G; Ciaramella V; Troiani T; Martinelli E; Belli V; Ciardiello F; Morgillo F
    Oncotarget; 2017 Apr; 8(14):23020-23032. PubMed ID: 28416737
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytotoxic chemotherapy may overcome the development of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) therapy.
    Kanda S; Horinouchi H; Fujiwara Y; Nokihara H; Yamamoto N; Sekine I; Kunitoh H; Kubota K; Tamura T; Ohe Y
    Lung Cancer; 2015 Sep; 89(3):287-93. PubMed ID: 26169499
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Frequency of EGFR T790M mutation and multimutational profiles of rebiopsy samples from non-small cell lung cancer developing acquired resistance to EGFR tyrosine kinase inhibitors in Japanese patients.
    Ko R; Kenmotsu H; Serizawa M; Koh Y; Wakuda K; Ono A; Taira T; Naito T; Murakami H; Isaka M; Endo M; Nakajima T; Ohde Y; Yamamoto N; Takahashi K; Takahashi T
    BMC Cancer; 2016 Nov; 16(1):864. PubMed ID: 27821131
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of insulin-like growth factor 1 receptor (IGF-1R) predicts poor responses to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer patients harboring activating EGFR mutations.
    Yeo CD; Park KH; Park CK; Lee SH; Kim SJ; Yoon HK; Lee YS; Lee EJ; Lee KY; Kim TJ
    Lung Cancer; 2015 Mar; 87(3):311-7. PubMed ID: 25617986
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Third generation EGFR TKIs in EGFR-mutated NSCLC: Where are we now and where are we going.
    Russo A; Franchina T; Ricciardi GRR; Smiroldo V; Picciotto M; Zanghì M; Rolfo C; Adamo V
    Crit Rev Oncol Hematol; 2017 Sep; 117():38-47. PubMed ID: 28807234
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Randomized Phase II Study Comparing Nivolumab With Carboplatin-Pemetrexed for Patients With EGFR Mutation-Positive Nonsquamous Non-Small-Cell Lung Cancer Who Acquire Resistance to Tyrosine Kinase Inhibitors Not Due to a Secondary T790M Mutation: Rationale and Protocol Design for the WJOG8515L Study.
    Hayashi H; Chiba Y; Sakai K; Fujita T; Yoshioka H; Sakai D; Kitagawa C; Naito T; Takeda K; Okamoto I; Mitsudomi T; Kawakami Y; Nishio K; Nakamura S; Yamamoto N; Nakagawa K
    Clin Lung Cancer; 2017 Nov; 18(6):719-723. PubMed ID: 28623122
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emerging treatment for advanced lung cancer with EGFR mutation.
    Inal C; Yilmaz E; Piperdi B; Perez-Soler R; Cheng H
    Expert Opin Emerg Drugs; 2015; 20(4):597-612. PubMed ID: 26153235
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acquired resistance to EGFR targeted therapy in non-small cell lung cancer: Mechanisms and therapeutic strategies.
    Lim SM; Syn NL; Cho BC; Soo RA
    Cancer Treat Rev; 2018 Apr; 65():1-10. PubMed ID: 29477930
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical approaches to treat patients with non-small cell lung cancer and epidermal growth factor receptor tyrosine kinase inhibitor acquired resistance.
    Tartarone A; Lerose R
    Ther Adv Respir Dis; 2015 Oct; 9(5):242-50. PubMed ID: 26016841
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical implications of T790M mutation in patients with acquired resistance to EGFR tyrosine kinase inhibitors.
    Sun JM; Ahn MJ; Choi YL; Ahn JS; Park K
    Lung Cancer; 2013 Nov; 82(2):294-8. PubMed ID: 24035188
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Second and third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer.
    Liao BC; Lin CC; Yang JC
    Curr Opin Oncol; 2015 Mar; 27(2):94-101. PubMed ID: 25611025
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 46.